Cartesian Therapeutics Inc.
RNAC | NASDAQ
$8.07
+$0.13 (+1.64%)
Sep 22, 2026, 10:50 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 2.8M | 38.91M | 26M | 110.78M | 85.08M | 16.6M |
Cost of Revenue | n/a | n/a | n/a | 2.04M | n/a | n/a |
Gross Profit | 2.8M | 38.91M | 26M | 108.74M | 85.08M | 16.6M |
Operating Income | -86.71M | -43.9M | -86.42M | 14.54M | -4.6M | -56.82M |
Interest Income | 6.58M | 7.39M | 4.96M | n/a | n/a | n/a |
Pretax Income | -139.5M | -77.14M | -238.71M | 34.77M | -9.72M | -68.88M |
Net Income | -130.3M | -77.42M | -219.71M | 35.38M | -25.69M | -68.88M |
Selling & General & Admin | 31.47M | 30.13M | 40.45M | 23.86M | 20.94M | 18.91M |
Research & Development | 58.03M | 45.11M | 71.26M | 72.38M | 68.74M | 54.51M |
Other Expenses | n/a | 7.58M | 710K | -2.04M | n/a | n/a |
Operating Expenses | 89.5M | 82.81M | 112.42M | 94.2M | 89.67M | 73.42M |
Interest Expense | n/a | n/a | 2.83M | 3.03M | 2.84M | 1.56M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 89.5M | 82.81M | 112.42M | 96.24M | 89.67M | 73.42M |
Income Tax Expense | -9.19M | 287K | -19M | -609K | 15.97M | n/a |
Shares Outstanding (Basic) | 25.97M | 25.91M | 5.17M | 4.02M | 3.18M | 2.81M |
Shares Outstanding (Diluted) | 25.97M | 23.69M | 5.17M | 4.05M | 3.18M | 2.81M |
EPS (Basic) | -5.02 | -2.99 | -49.76 | 7.33 | -6.74 | -20.42 |
EPS (Diluted) | -5.02 | -3.29 | -49.76 | 3 | -6.60 | -20.42 |
EBITDA | -136.54M | -75.99M | -235.03M | 39.84M | -5.16M | -65.59M |
EBIT | -139.5M | -77.14M | -235.88M | 37.8M | -6.88M | -67.32M |
Depreciation & Amortization | 2.96M | 1.15M | 843K | 2.04M | 1.72M | 1.73M |
Add to Watchlist
Select watchlists to add or remove RNAC